Following a single CD19 CAR-T infusion treatment, the European Scleroderma Study Group (EUSTAR) activity scores of all SSc patients and disease indexes of SLE and IIM patients decreased significantly, with only a few mild cytokine release syndrome (CRS) occurrences, confirming the broad-spectrum anti-autoimmune effects and safety of this therapy. Here, CD19 is linked to systemic sclerosis.